Trial Profile
Phase II Trial of Pomalidomide in GEP-defined High-risk Multiple Myeloma That is Relapsing or Refractory to Prior Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2021
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Sep 2013 Status changed from suspended to completed as reported by ClinicalTrials.gov.
- 01 Sep 2013 Status changed from suspended to completed as reported by ClinicalTrials.gov.
- 21 Aug 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.